Brief: Gain Therapeutics Presents New Preclinical Data Demonstrating Reduction Of Plasma Neurodegeneration Biomarker NFL After Administration Of Its Drug Candidate GT-02287 In GBA1 Parkinson’S Disease Model
28/08/2023 12:06
Aug 28 (Reuters) - Gain Therapeutics Inc GANX.O :
* GAIN THERAPEUTICS PRESENTS NEW PRECLINICAL DATA
DEMONSTRATING A
REDUCTION OF PLASMA NEURODEGENERATION BIOMARKER NFL AFTER
ADMINISTRATION OF ITS DRUG CANDIDATE GT-02287 IN GBA1
PARKINSON’S DISEASE MODEL
* GAIN THERAPEUTICS INC - GAIN REMAINS ON TRACK TO BEGIN A
PHASE 1
CLINICAL STUDY OF GT-02287 LATER THIS YEAR
Source text for Eikon: ID:nGNX1J027W
Further company coverage: GANX.O
Recent news on Gain Therapeutics
See all newsU.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Gain Therapeutics climbs on narrower-than-expected quarterly loss
Gain Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall